Revolutionary record will accelerate application of gene mapping, biomarker discovery, growth profiling, and glass biopsy analysis
ANN ARBOR, Mich.–(Antara/BUSINESS WIRE)– Swift Biosciences, a heading provider of innovative library prep solutions for genomic sequencing, currently announced a launch of Accel-NGS® 2S Indexed Adapters, a new portfolio of indices that significantly improves multiplexed next-generation sequencing on Illumina® platforms. This singular set of indices provides a largest set of commercially available, singular indices for high-throughput genomic sequencing applications, enabling users to reliably multiplex adult to 96 single-indexed samples and 768 dual-indexed samples per run. This industry-leading record meets a flourishing direct from investigate and core laboratories to pool incomparable representation numbers per instrument run, enabling some-more careful sequencing while providing improved information accuracy.
Multiplex DNA sequencing is a common workflow in that mixed samples are labeled and pooled together into a singular run to boost throughput and to revoke sequencing cost per sample. Recent peer-reviewed publications have shown other commercially accessible indices are impacted by multiplexing errors, called “index hopping”—the misassignment of sequencing reads to a wrong sample. Additionally, comparison multiplex DNA sequencing technologies are disposed to other sequencing errors, compounding a misassignment blunder rates. As sequencing platforms boost capacity, such as Illumina’s newest platform, NovaSeq™, a need for high difficult indices to capacitate vast numbers of samples to be multiplexed is in vast demand.
Researchers during Swift Biosciences pronounced a Accel-NGS 2S Indexed Adapters are a set of 96 singular indices optimized to work in multiple with Illumina TruSeq® P5 adapters to yield adult to 768 singular dual-index combinations. These new indices are optimized to yield incomparable coherence to routine between 96-768 singly tagged samples per run and can accommodate a wider operation of projects with varying sequencing depth. Additionally, a singular settlement eliminates misassignment and index hopping, an emanate specific to Illumina’s settlement upsurge cells. These improvements yield incomparable attraction to detect low magnitude variants as good as incomparable fealty to accelerate de-multiplexing during information analysis.
“Our idea during Swift is to capacitate scientists to beget a top peculiarity information from any representation type, vouchsafing them pull a bounds of their science,” settled Timothy Harkins, boss and CEO of Swift Biosciences. “Our new Accel-NGS 2S Indexed Adapters tighten a throughput and cost opening on Illumina platforms, and when total with Accel-NGS 2S technologies, all forms of sequencing laboratories are generating aloft peculiarity information in a most some-more cost-effective manner.”
First Commercial Order
The new Accel-NGS 2S Indexed Adapters are commercially accessible now. The initial blurb sequence shipped to Shanghai Nanodigmbio Biotechnology Co. LTD, a placement channel partner for Swift’s product portfolio in China. Shanghai Nanodigmbio Biotechnology is one of a fastest flourishing sequencing markets and a vicious actor in genomics and illness research. In 2016, China denounced a “Five-Year Plan” with a vital concentration on pointing medicine, a fast flourishing focal area of genomics that will beam destiny evidence and healing development.
“Swift’s new indexed adapters yield a vital advantage to researchers conducting aim improvement sequencing,” pronounced Chance Wu, CEO of Shanghai Nanodigmbio Biotechnology Company. “Now it will be probable for researchers to maximize a series of exomes per run to fast consult incomparable representation sets in a some-more cost-effective manner.”
View source chronicle on businesswire.com: http://www.businesswire.com/news/home/20170803006256/en/
Lambert, Edwards Associates
Darby Wagner, (616) 258-5779
Source: Swift Biosciences
Article source: http://www.antaranews.com/en/news/112122/swift-biosciences-announces-new-industry-leading-indexed-adapters-for-sequencing-larger-numbers-of-samples-in-a-single-run